

January 27, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400 001

Sub: Intimation of Conference Call for Investors/ Analysts for Q3 & 9M FY23

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Thursday, February 02, 2023 at 05:00 pm IST to discuss the financial and operating performance for Q3 & 9M FY23.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Rajat Kalra
Company Secretary and Legal Head

Encl: As above


Q3 & 9M FY23 Earnings Conference Call Thursday, February 2, 2023 at 5:00pm IST

Gurugram, Jan 27, 2023:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q3 & 9M FY23 results. DLPL will be represented by Dr. Om Prakash Manchanda – Managing Director, Mr. Bharath U – Chief Executive Officer, Mr. Ved Prakash Goel – Group Chief Financial Officer, Mr. Shankha Banerjee – CEO of Suburban and other group companies and Mr. Rajat Kalra – Company Secretary & Head of Investor Relations.

The conference call will be initiated with a discussion by the management on Q3 & 9M FY23 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none"> ● 5:00pm IST on Thursday, February 2, 2023
Pre-registration	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <div style="text-align: center;">  Click here to ExpressJoin the Call </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Universal Access	<ul style="list-style-type: none"> ● +91 22 6280 1141 ● +91 22 7115 8042
Conference dial-in International Toll Number	<ul style="list-style-type: none"> ● USA – 18667462133 ● UK – 08081011573 ● Singapore – 8001012045 ● Hong Kong – 800964448
Replay	<ul style="list-style-type: none"> ● Dial in No. +91 22 7194 5757 ● 52223 (passcode) ● Valid from Feb 2, 2023 to Feb 9, 2023

-ENDS-

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2022.

As on March 31, 2022, DLPL's has 277 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). In FY21 & FY22, DLPL collected and processed approximately 49.7 million samples and 66 million samples from approximately 20.3 million and 27.3 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

For further information, please contact:

Ved Goel / Rajat Kalra
Dr. Lal PathLabs Limited
E-mail: ved.goel@lalpathlabs.com
rajat.kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki
CDR India
Email: siddharth@cdr-india.com
nishid@cdr-india.com

Disclaimer: Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.